Poxviridae

orted by funding and products from the Australian company Medical Ethics. This work was also supported by the Aragón Government (A15_20R and A15_23R). Institutional Review Board Statement: All the procedures were supervised and approved by the Ethics Advisory Commission for Animal Experimentation (no. PI33/21), the Biosafety Committee and the Occupational Risk Prevention Unit of the University of Zaragoza, in accordance with current regulations regarding these procedures, aspects: R.D. 53/2013 (which aligns with the European Union Directive 2010/63 on the protection of animals used for experimental and other scientific purposes), Law 31/1995, R.D. 664/1997, R.D. 1299/2006. Informed Consent Statement: Not applicable. Data Availability Statement: The raw data supporting the conclusions of this article will be made available by the authors on request. Acknowledgments: The authors would like to acknowledge the interns of the Ruminant Clinical Service of the Veterinary Faculty of Zaragoza involved in this study. They would also like to thank Maria Ángeles Lostao for her collaboration in the laboratory work. Conflicts of Interest: The authors declare no conflicts of interest, although P.A.W. has provided occasional advisory service to Medical Ethics Australia. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. References 1. Bala, J.A.; Balakrishnan, K.N.; Abdullah, A.A.; Mohamed, R.; Haron, A.W.; Jesse, F.F.A.; Nordin, M.M.; Mohd-Azmi, M.L. The re-emerging of orf virus infection: A call for surveillance, vaccination and effective control measures. Microb. Pathog. 2018, 120, 55–63. [CrossRef] 2. Bergqvist, C.; Kurban, M.; Abbas, O. Orf virus infection.

…Orf virus belongs to the Facultad de Veterinaria de Zaragoza, C/Miguel Servet 177, Zaragoza, 50013, genus Parapoxvirus, family Poxviridae, sub-family Chordopoxvirinae.1 It is Spain a pathogen with worldwide distribution…

lable, pre-treatment data were included as a co-variate. Baseline data were defined as the latest measurement of a given variable before treatment was administered. The statistical model included treatment, sex (except for parameters only measured in one sex), and treatment-by-sex interactions as fixed effects, while the repeated measures ANOVA model included treatment, sex and time (and their 2-way and 3-way interac- tions) as fixed effects. Data were compared either within or across sex depending on observed interactions. Models were selected using backwards elimination where 3-way and 2-way interaction terms with the highest p-Value were sequentially dropped from the model. The process was performed hierarchically starting with the 3-way interaction terms using a threshold p-Value of 0.1, as required by regulatory guidelines. Model selection was stopped when any of the following occurred: (i) all interaction terms at the highest level had a p-Value < 0.1; (ii) no interaction terms remained in the model. The statistical model was therefore: Parameter = Baseline_variables + Treatment + Sex + Time + Treatment:Sex + Treat- ment:Time + Sex:Time + Treatment:Sex:Time + Residual_Error Least squares means were compared at a significance level of p < 0.1 in the first instance apart from treatment by sex by time point, which was compared at p < 0.05 in the first instance. For the repeated measures models, most residual error patterns were selected based on a comparison of Akaike Information Criteria (AIC) output for models containing an unstructured (UN), autoregressive (AR; 1), variance components (VC) and independent residual error pattern (with the lowest AIC preferred among the possible covariance matrices). The denominator degrees of freedom in the covariance pattern